Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients

Abstract

In our study, over 83% Chinese and 68% US GBC patients had actionable alterations that could potentially guide and influence personalized treatment options. The identification of high TMB, <i>ERBB2</i>, <i>CDKN2A/B</i>, PI3K/mTOR pathway and DNA repair mutations indicated that both Chinese and US GBC patients may benefit from targeted or immune checkpoint inhibitors.